Approval · Notice of Compliance 23222 · 2020
VOLULYTE: Notice of Compliance 23222
Issued February 18, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23222
- Date
- February 18, 2020
- Company
- Fresenius Kabi Canada LtdToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Response to the advisement letter sent by health canada on january 24, 2019 requesting change to indication and the removal of pediatric dosing information
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VOLULYTE | Not yet assigned | — |
Medicinal ingredients
- HYDROXYETHYL STARCH 6 PER